INTRODUCTION

Optimal pain management is an essential component of enhanced recovery after surgery protocols (ERAS) that are becoming standard of care because they have been shown to reduce postoperative complications and expedite recovery. However, postoperative pain is still inadequately managed. Opioids remain the mainstay of perioperative pain management, despite well-recognized adverse events including nausea, vomiting, pruritus, sedation, constipation, respiratory depression, and opioid-induced hyperalgesia. In addition, opioid misuse and abuse has reached epidemic status. The surgeon’s contribution to the opioid epidemic is an undeniable reality. While surgeons are responsible for 10% of all opioid prescriptions, the most common reason for new opioid prescriptions is for acute postoperative pain. In 2017, the Commission on Combating Drug Addiction and the Opioid Crisis reported that “with approximately 142 Americans dying every day [from the opioid crisis], America is enduring a death toll equal to September 11th every three weeks.” According to the US Center for Disease Control, 130 deaths per day are attributable to the opioid epidemic. In 2017, among 70,237 drug overdose deaths reported in 50 states, 47,600 (67.8%) involved an opioid. Two focused areas of concern describe potential surgeon contribution to the problem. The first is the creation of chronic opioid addiction in postsurgical patients who were previously opioid naive, termed “new persistent use.” For patients undergoing plastic surgery, specifically, the rates of new persistent use have been reproducibly demonstrated to be between 5% and 13% across a variety of plastic surgery procedures. For surgeons operating on pediatric patients, it is also important to note that the pediatric population is not immune to the development of new persistent use, with rates between 2% and 15% depending on the operation. Second, overprescribing by surgeons results in the inadvertent distribution of unused opioids into the community. Overprescribing increases the risk of “diversion” or the redirection of legally obtained prescription opioids for illicit abuse. Plastic surgeons are uniquely positioned to play an important role in the reduction of the opioid epidemic because of the efficacy of multimodal analgesia and ERAS protocols for plastic surgery procedures and because of the ability to influence multispecialty surgical collaboration. Multimodal analgesia is particularly applicable and effective for plastic surgery procedures, and the most prevalent strategies are reviewed herein.

EVIDENCE-BASED STRATEGIES FOR EFFECTIVE PAIN MANAGEMENT

Multimodal analgesia is a strategy that reduces reliance on opioids through the use of non-opioid analgesics.
that have different mechanisms of action. Multimodal analgesia is directed toward 4 goals: (1) improvement in the patient experience through better pain control, (2) reduction in postoperative morbidity and mortality, (3) reduction in healthcare costs, and (4) decreased physician-contribution to the global opioid epidemic.

Multimodal analgesia regimens are both patient- and procedure-specific and utilize varying combinations of local and/or regional analgesic techniques and non-opioid analgesics (eg, acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase [COX]-2–specific inhibitors) and analgesic adjuncts (eg, dexamethasone, gabapentinoids). It is recommended that all surgical patients should receive “basic analgesics”, which include acetaminophen and either an NSAID or a COX-2-specific inhibitor unless there is a contraindication in a “scheduled” manner, perioperatively, preferentially over “as needed” or pro re nata administration. In addition, patients should receive some form of local/regional anesthetic technique (eg, surgical site infiltration, interfascial plane block). Furthermore, it is necessary to balance the invasiveness of the analgesic technique with the expected severity of postoperative pain and balance the efficacy of the analgesic technique and the potential adverse effects including the influence on ambulation. An example of how to incorporate these principles is presented in a sample multimodal analgesia protocol for abdominal wall reconstruction (Fig. 1).

### LOCAL AND REGIONAL ANALGESIC TECHNIQUES

With rare exception, local and/or regional anesthesia can and should be used as a matter of routine for most plastic surgery procedures. Local anesthetic medications inhibit neuronal action potentials via voltage-gated sodium channel blockade. The mode of administration can occur via single injection techniques or by catheter-based infusion techniques that administer local anesthetic either intermittently or continuously. Special consideration must be paid toward refining delivery techniques for local anesthetic administration to optimize patient comfort, especially for awake procedures.

Evidence exists supporting the role of local anesthetics for opioid reduction, decreased postoperative nausea and vomiting (PONV), decreased pain scores, decreased lengths of stay, decreased rates of certain postoperative complications, and decreased healthcare costs across a variety of plastic surgery procedures. Therefore, it is imperative that the surgeon be familiar with anatomy and injection techniques and engage in a multidisciplinary approach to maximize the number of patients receiving regional anesthesia when clinically indicated. Joshi et al highlight that the persistent underuse of peripheral nerve blocks can be at least partially overcome by surgeon familiarity and administration of intraoperative interfascial plane blocks and appropriately performed surgical site infiltration. Technical considerations for surgical site infiltration as well as interfascial plane blocks have been recently reviewed.

The challenge of short duration of action for most local anesthetics (approximately 8–12 hours) has been met by catheter infusion techniques or through the development of extended release formulations such as liposomal bupivacaine. In a systematic review of 28 publications encompassing plastic surgery procedures, catheter-based infusion of local anesthetic resulted in an opioid-sparing effect in 92% of studies reviewed.

### Multimodal Analgesia Protocol for Abdominal Wall Reconstruction

| Stage | Procedure |
|-------|-----------|
| **Preoperative** | At home: 300 mg oral gabapentin**  
In preoperative holding: 1500 mg acetaminophen* (2 hours prior) + 300 mg gabapentin** (2 hours prior) + 400 mg celecoxib*** (20 minutes prior) |
| **Intraoperative** | Multi-planar field block + TAP block with liposomal bupivacaine + 30 mg IV ketorolac + 8 mg IV dexamethasone† |
| **Day 0/Day of Surgery** | 200 mg celecoxib*** + 1000 mg acetaminophen* + 300 mg gabapentin** + 5 mg oxycodone PRN + 100 mg docusate + 8 mg ondansetron |
| **Day 1 and After** | 200 mg celecoxib*** TID x 14 days + 1000 mg acetaminophen* every 6 hours x 14 days + 300 mg gabapentin** TID x 14 days + 5 mg oxycodone every 4 hours PRN + 100 mg docusate BID x 7 days + 8 mg ondansetron every 8 hours PRN |

* Acetaminophen: caution with liver disease. Preoperative preferred in liquid form. 2nd “Day 0” acetaminophen dose 6 h after first.  
** Gabapentin: Do not use in patients over 70 years or those with reduced renal function. Adjust for renal function.  
*** Celecoxib: consider cardiovascular risk, gastroesophageal ulcer history, renal function, hepatic function. 2nd “Day 0” celecoxib dose 12 h after first.  
† Dexamethasone: improves pain control, reduces postoperative nausea/vomiting, anti-inflammatory. No significant effect on blood glucose.

Definitions: TAP: transversus abdominis plane, TID: three times per day, BID: twice per day, PRN: as needed, h: hours

Fig. 1. Multimodal analgesia protocol for abdominal wall reconstruction.
Recent evidence has emerged highlighting the benefit of extended release formulations due to prolonged duration of analgesia, ease of single-injection technique that does not necessitate catheter placement, and long-term cost-effectiveness. A 2016 meta-analysis demonstrated safety, tolerability, and either comparable or increased efficacy for pain control for the use of liposomal bupivacaine in plastic surgery. Liposomal bupivacaine for regional blockade in the transversus abdominis plane is commonly used in abdominal procedures such as abdominally based microsurgical breast reconstruction and abdominal wall reconstruction, demonstrating opioid reduction, decreased lengths of stay, and improved pain scores over traditional catheter-based infusion techniques without increases in wound complications. Studies have demonstrated either equivalent or long-term cost-effectiveness of liposomal bupivacaine including decreased length of stay and lower 30-day readmission rates.

It is not only critical for the plastic surgeon to become familiar with techniques of local and regional anesthesia but also frequently refresh knowledge of the management of complications associated with these medications. Moreover, frontline providers in both the inpatient and office setting must be educated on signs of local anesthetic toxicity, with protocols in place for management.

Recommendations Summary
Use of local and/or regional anesthesia is highly recommended. For many plastic surgery procedures, single regional injection of extended release formulations has the advantage of long duration of action without the need for catheter placement and management. Surgeons must become familiar with regional anatomy and techniques and implement protocols including refresher education for frontline providers on symptoms and management of local anesthetic toxicity.

NSAIDs and COX-2-Specific Inhibitors
NSAIDs form the basis of an optimal multimodal analgesic technique. For core plastic surgery procedures, the use of celecoxib has been shown to reduce pain scores, reduce opioid consumption, expedite return of bowel function and return to activities of daily living, and improve patient satisfaction. In outpatient breast plastic surgery, the use of NSAIDs within a preoperative multimodal analgesia protocol reduced opioid requirements in the postanesthesia care unit by 40% and improved pain scores by 40%. NSAIDs are more effective than other adjunct oral medications with lower numbers needed to treat.

COX-2 selective inhibitors have a more favorable side effect profile with regard to bleeding than nonselective modalities but are contraindicated in those with preexisting coronary artery disease because of their association with higher rates of cardiac events. NSAIDs and COX-2 selective inhibitors should also be avoided in those with acute or chronic renal disease, and iatrogenic acute renal injury is also a consideration for older perioperative patients, though its absolute risk is not well-defined for plastic surgery procedures. Controversy surrounds the risk of impaired platelet function and potential surgical bleeding risk associated with NSAIDs, specifically as it relates to reduction mammoplasty. However, there remains no high-level evidence to support their contraindication in most plastic surgical patients, and several large reviews have concluded that there is no difference in hematoma rates associated with NSAID use. A recent meta-analysis reviewing 15 studies with 3064 cumulative patients demonstrated no increase in hematoma with the use of several types of NSAIDs across a variety of plastic surgical procedures including breast surgery. In breast and body contouring procedures, Kelley et al reviewed 106,279 patients; among these, 4,924 (4.6%) patients received postoperative ketorolac. Multivariable regression analysis demonstrated that ketorolac was not associated with hematoma (odds ratio, 1.20; 95% CI, 0.99–1.46; P > 0.05), concluding that the benefits of NSAID use outweigh the risks. In sum, the anecdotal frequency of hematoma formation secondary to NSAIDs is overestimated, with evidence supporting the use of NSAIDs in the appropriately selected patient.

Recommendations Summary
The benefits of NSAID or COX-2 selective inhibitor use in the appropriately selected patient outweigh the risks. Preoperative, intraoperative, and postoperative incorporation of these analgesics into multimodal analgesia regimens is recommended.

Acetaminophen
Acetaminophen is an effective perioperative analgesic with efficacy for both pain control and opioid reduction across all surgical specialties. The mechanism of action is unknown, although it is thought to be from activation of descending serotonergic pathways and inhibition of COX-mediated prostaglandin synthesis in the central nervous system. The safety profile of acetaminophen is favorable, with the exception of hepatotoxicity above the maximum dosage of 4 g per 24 hours. Avoiding acetaminophen usage in patients with known liver disease should be considered. Controversy has centered around the effectiveness of oral versus parenteral formulations and its relation to cost. A recent meta-analysis demonstrates no clear advantage of parenteral administration over oral administration for appropriately selected patients for the indication of perioperative pain control. Oral administration has been reproducibly demonstrated to be effective for preoperative and postoperative analgesia, specifically. Oral dosage protocols range from 650 to 1000 mg and favor “around-the-clock” administration, typically every 6 hours. There have been no high-level studies comparing the effectiveness of dosage differences for the indication of perioperative pain management. With “around-the-clock” acetaminophen regimens, it is recommended to avoid the use of acetaminophen–opioid combination formulations for breakthrough pain because of the risk of inadvertent acetaminophen overdose. This warrants special mention.
because combination formulations are the most commonly prescribed by plastic surgeons for breakthrough pain.56

Recommendations Summary
Acetaminophen should be used routinely for preoperative, intraoperative, and postoperative analgesia in an “around-the-clock” manner to reduce pain and opioid consumption. It is not recommended to prescribe acetaminophen–opioid combination tablets for breakthrough pain with this regimen because of the risk of acetaminophen overdose. Both oral and parenteral formulations are effective. Consideration should be given to avoid acetaminophen in patients with known liver disease.

GABAPENTINOIDS
Gabapentin is the most widely used anticonvulsant as an adjunct perioperative pain medication. In the perioperative setting, gabapentin decreases postoperative pain and opioid consumption, as well as PONV.36,51,52 A meta-analysis encompassing 18 studies and 1,181 patients demonstrated that perioperative gabapentin resulted in 35% reduction in total opioid consumption and pain within the first 24 hours after surgery while simultaneously increasing early ambulation.53 A large randomized controlled trial encompassing a variety of surgical procedures demonstrated effectiveness of perioperative gabapentin toward supporting postoperative opioid cessation, with a regimen consisting of 1,200 mg preoperatively and 600 mg 3 times daily postoperatively for 10 doses.54 In the burn population, gabapentin is uniquely beneficial because of its ability to reduce burn-associated pruritus, in addition to decreasing opioid consumption.55,56

Of note, most studies assessing the analgesic benefits of gabapentinoids did not use the basic analgesics (ie, acetaminophen and NSAIDs) or local anesthetic techniques. The benefits of gabapentinoids over basic analgesic techniques appear to be limited.12 Furthermore, gabapentinoids are associated with several adverse effects including dizziness, somnolence, and respiratory depression. For this reason, gabapentinoids should be used selectively when basic analgesic techniques are not possible or contraindicated and patients are at a high risk of persistent postoperative pain.12 Also, it is recommended to avoid or dose-reduce the medication for the elderly, patients with significant comorbidities, and those with reduced lung function including chronic obstructive pulmonary disease or known or suspected obstructive sleep apnea.57

Recommendations Summary
Gabapentin is a useful analgesic adjunct in the preoperative and postoperative setting that can reduce opioid consumption and improve the patient’s postoperative experience. However, gabapentin should be used in selective patient populations and surgical procedures that are at a high risk of persistent postoperative pain. In these situations, gabapentin should not be avoided because of physician lack of familiarity with the drug. Concerns with gabapentinoids include dizziness and sedation, as well as potential for respiratory depression, particularly in the patients with significant comorbidities, the elderly, and patients with known or suspected reduced lung function such as chronic obstructive pulmonary disease or obstructive sleep apnea.

DEXAMETHASONE
Glucocorticoids reduce postoperative pain through anti-inflammatory mechanisms and possess antiemetic properties, serving as a key adjunct for PONV prophylaxis.59 A 2013 meta-analysis demonstrated that postoperative patients have decreased pain scores and opioid consumption when dexamethasone is included as a multimodal adjunct.59 Few studies address the role of dexamethasone in plastic surgery, specifically. A recent prospective, double-blind randomized trial in head and neck microvascular reconstruction similarly demonstrated decreased pain and opioid consumption after dexamethasone inclusion. However, hyperglycemia and insulin requirements were problematic for patients in the treatment group, leading the authors to conclude that the risks for reconstructive patients outweighed the benefits.60 In contrast, systematic reviews have concluded that the benefits from dexamethasone outweigh the concerns of hyperglycemia, except for patients with brittle diabetes mellitus. No evidence currently exists correlating dexamethasone use with an increased occurrence of postoperative wound infection or wound healing delay.62

Recommendations Summary
Dexamethasone reduces pain and opioid consumption and reduces PONV. A single intraoperative dose of dexamethasone 8 mg, IV should be considered as an integral component of multimodal analgesia and antiemetic prophylaxis for all procedures unless there is a contraindication (eg, uncontrolled diabetes mellitus). Those at risk for complications associated with postoperative hyperglycemia represent less ideal candidates.

WHAT PATIENTS SHOULD KNOW
Early communication, establishment of expectations, and patient engagement are necessary for multimodal analgesia to be most effective. In 2017, the final report from The President’s Commission on Combating Drug Addiction and the Opioid Crisis cited the lack of patient education as a significant contributor to the current epidemic. Specially, that “patients and their families are not often fully informed regarding whether their prescriptions are opioids, the risks of opioid addiction or overdose, control and diversion, dose escalation, or the risks of use with alcohol or benzodiazepines.”63 For plastic surgery patients, specific points that should routinely be communicated to patients in the preoperative clinic setting include (1) discussion of the medical risks of opioids, in terms of known postoperative side effects and potential for abuse, (2) purpose and importance of alternative medications and regional procedures, and (3) proper medication storage and proper disposal (Table 1).
Table 1. Recommended Counseling Points Regarding Multimodal Analgesia and Appropriate Use of Opioid Medications for Plastic Surgery Patients and Families

| Topic | Recommended Details |
|-------|---------------------|
| Opioid-related adverse events | Common side effects are nausea, vomiting, constipation, pruritus, sedation, dizziness. Pain regimens based on opioids increase the risk of respiratory depression, venous thromboembolism, postoperative infections, longer length of stay, and increased costs. |
| New persistent use and opioid addiction | 5%-13% of previously opioid naive plastic surgery patients develop new persistent use. |
| Opioids for breakthrough pain only | Smaller prescription sizes do not diminish quality of pain control when used in conjunction with multimodal analgesia. |
| Benefits of regional analgesia | Discuss what to expect when, so that patients are well informed before any preoperative procedures. Empower patients with drug name, class, dose, duration, and evidence-based benefits. |
| Purpose of adjunct multimodal analgesia pain medications | Most instances of diversion are through family, friends, and acquaintances. “It can happen to anyone.” |
| Proper opioid storage in a locked location | Rediscuss diversion. Patient education materials available are on the CDC website for disposal options. |

Counseling should occur in the preoperative setting and be reiterated postoperatively.

Education regarding proper storage and disposal are linked to risk minimization for opioid diversion. A recent meta-analysis of 7 different surgical procedures demonstrated that 42%-71% of opioid tablets that are prescribed are not used after surgery.82 In a study of secondary breast procedures and breast reduction, patients reported an average of 12-18 leftover tablets per operation.65 Further, over 70% of postoperative prescription opioids are not safely stored in a locked location.82 The majority of patients do not know how to safely dispose of unused medication. This prevalence of overprescribed, excess tablets is problematic but provides an opportunity for intervention. Interestingly, the simple act of providing smaller prescriptions has been shown to decrease opioid consumption without impacting quality of pain control.64 A recent prospective trial demonstrated that preoperative education results in 20% reduction of opioid consumption.64 Likewise, patient education has also been shown to increase the frequency of proper disposal by 22%.65

Unfortunately, a recent review of prescribing practices in plastic surgery notes that only 45% and 37% of surgeons report routinely counseling their patients on the risks of addiction and secure medication storage, respectively.48

**Recommendations Summary**

Patients should be informed that overprescribing does not improve quality of pain control. It is imperative to engage patients early to communicate known adverse effects associated with opioid use. Further, patients should be counseled to expect multiple opportunities for alternative pain management interventions throughout their preoperative, intraoperative, and postoperative course. Counseling regarding proper medication storage and disposal is the responsibility of every prescription provider.

**CONCLUSIONS**

Multimodal analgesia with non-opioid analgesics and local anesthetic techniques should be incorporated into

### Table 2. Recommendations Summary for Principles of Multimodal Analgesia

| Multimodal Agent | Useful Indications and Timing | Important Considerations and Contraindications |
|------------------|-------------------------------|-----------------------------------------------|
| Local and regional anesthetic | All patients should receive local or regional anesthetic. Recommended for all patients unless contraindicated. Effective in “scheduled” manner perioperatively. Can be implemented in preoperative, intraoperative, and postoperative settings. | Balance invasiveness of technique with severity of pain. Refresh providers on signs/symptoms of local anesthetic toxicity. COX-2 inhibitors should be avoided in patients with coronary artery disease. Does not increase bleeding complications. |
| Nonsteroidal anti-inflammatories drugs and COX-2 selective inhibitors | For operations at higher risk for persistent postoperative pain. | Use caution in patients with known liver disease. It is not recommended to prescribe combination opioid-acetaminophen medications with a scheduled acetaminophen regimen to avoid inadvertent toxicity. Adverse events include dizziness, somnolence, and decreased respiration. Caution advised with elderly patients and those with reduced lung function. Dose-adjusted for renal function. |
| Acetaminophen | Recommended for all patients unless contraindicated. Effective in “scheduled” manner perioperatively. Can be implemented in preoperative, intraoperative, and postoperative settings. | Do not exceed 4 g in 24 h. |
| Gabapentinoids | Use caution in patients with known liver disease. It is not recommended to prescribe combination opioid-acetaminophen medications with a scheduled acetaminophen regimen to avoid inadvertent toxicity. Adverse events include dizziness, somnolence, and decreased respiration. Caution advised with elderly patients and those with reduced lung function. Dose-adjusted for renal function. | Monitor for perioperative hyperglycemia, but no evidence to strongly support this as a contraindication. |
| Dexamethasone | Single intraoperative dose useful for analgesia and antiemetic prophylaxis. Consider especially for patients with history of PONV. | |
every surgical procedure, with opioids prescribed only for rescue analgesia (ie, for breakthrough pain) and not as a primary pain management strategy. While direct comparisons between protocols do not exist for a majority of plastic surgery operations, principles of multimodal analgesia carry through (Table 2). It is important to note that interventions should occur across 3 time points in the preoperative, intraoperative, and postoperative settings and in multidisciplinary collaboration. Standardization of protocols increases efficiency and compliance across a healthcare system and is also known to decrease cost.” Therefore, it is recommended to develop procedure-specific protocols for one’s practice that are well-communicated with patients, families, and collaborative practitioners. Although outside the scope of this article, it is critical to identify patients at a higher risk of postoperative pain and emphasize that approach to pain therapy based exclusively on pain scores is inappropriate.

Jeffrey E. Janis, MD, FACS
The Ohio State University Wexner Medical Center
915 Olentangy River Road, Suite 2100
Columbus, OH 43212
E-mail: Jeffrey.Janis@osumc.edu

ACKNOWLEDGMENTS

J.B. was supported by the National Institutes of Health (NIH) T32AI106704-01A1, NIH F32HL144120-01A1, and the Ohio State University President’s Postdoctoral Scholar Program.

REFERENCES

1. Joshi GP, Kehlet H. Enhanced recovery pathways: looking into the future. Anesth Analg. 2019;128:5–7.
2. Joshi GP, Kehlet H. Postoperative pain management in the era of ERAS: an overview. Best Pract Res Clin Anaesthesiol. 2019;33:259–267.
3. Alexander JC, Patel B, Joshi GP. Perioperative use of opioids: current controversies and concerns. Best Pract Res Clin Anaesthesiol. 2019;33:341–351.
4. Levy B, Paulozzi L, Mack KA, et al. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med. 2015;49:409–413.
5. Waljee JF, Li L, Brummett CM, et al. Iatrogenic opioid dependence in the United States: are surgeons the gatekeepers? Ann Surg. 2017;265:728–730.
6. Christie C, Baker C, Cooper R, et al. The President’s commission on combatting drug addiction and the opioid crisis: final report. 2017. Available at https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-1-2017.pdf. Accessed May 1, 2020.
7. Centers for Disease Control and Prevention. 2018 Annual surveillance report of drug-related deaths and outcomes—United States. Surveillance special report 2. Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. 2018. Available at https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf. Accessed May 1, 2020.
8. Scholl L, Seth P, Karlisa M, et al. Drug and opioid-involved overdose deaths—United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67:1410–1427.
9. Johnson SP, Chung KC, Zhong L, et al. Risk of prolonged opioid use among opioid-naïve patients following common hand surgery procedures. J Hand Surg Am. 2016;41:947.e3–957.e3.
10. Bennett KG, Kelley BP, Vick AD, et al. Persistent opioid use and high-risk prescribing in body contouring patients. Plast Reconstr Surg. 2019;143:87–96.
11. Harbaugh CM, Lee JS, Hu HM, et al. Persistent opioid use among pediatric patients after surgery. Pediatrics. 2018;141:e20172439.
12. Bennett KG, Harbaugh CM, Hu HM, et al. Persistent opioid use among children, adolescents, and young adults after common cleft operations. J Craniofac Surg. 2018;29:1697–1701.
13. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–163.
14. Bartels K, Mayes LM, Dingmann C, et al. Opioid use and storage patterns by patients after hospital discharge following surgery. Plast Reconstr Surg. 2018;143(4 Suppl 2):68–78.
15. Rosero EB, Joshi GP. Preemptive, preventive, multimodal analgesia: what do they really mean? Plast Reconstr Surg. 2014;134(4 Suppl 2):858–938.
16. Joshi GP, Schug SA, Kehlet H. Procedure-specific pain management and outcomes strategies. Best Pract Res Clin Anaesthesiol. 2014;28:191–201.
17. Joshi GP, Kehlet H; PROSPECT Working Group. Guidelines for perioperative pain management: need for re-evaluation. Br J Anaesth. 2017;119:703–706.
18. Lalonde D, Wong A. Local anesthetics: what’s new in minimal pain injection and best evidence in pain control. Plast Reconstr Surg. 2014;134(4 Suppl 2):408–498.
19. Farias-Eisner G, Kao K, Pan J, et al. Intraoperative techniques for the plastic surgeon to improve pain control in breast surgery. Plast Reconstr Surg Glob Open. 2017;5:e1522.
20. Rivedal DD, Nayar HS, Israel JS, et al. Paravertebral block associated with decreased opioid use and less nausea and vomiting after reduction mammoplasty. J Surg Res. 2018;228:307–313.
21. Joshi GP, Kehlet H, Rawal N. Surgeon-administered regional analgesia to replace anaesthesiast-administered regional analgesia: need for communication and collaboration. Br J Anaesth. 2019;123:707–709.
22. Joshi GP, Machi A. Surgical site infiltration: a neuroanatomical approach. Best Pract Res Clin Anaesthesiol. 2019;33:317–324.
23. Machi A, Joshi GP. Interfascial plane blocks. Best Pract Res Clin Anaesthesiol. 2019;33:303–315.
24. Roy CF, Azzi AJ, Davison P A review of wound infusion with local anesthetics in plastic surgery. Ann Plast Surg. 2019;83:e110–e117.
25. Joshi GP, Janis JE, Haas EM, et al. Surgical site infiltration for abdominal surgery: a novel neuroanatomical-based approach. Plast Reconstr Surg Glob Open. 2016;4:e1181.
26. Sallibian AA, Frey JD, Thanik VD, et al. Transversus abdominis plane blocks in microsurgical breast reconstruction: analysis of pain, narcotic consumption, length of stay, and cost. Plast Reconstr Surg. 2018;142:252e–263e.
27. Gatherwright J, Knackstedt RW, Ghaznavi AM, et al. Prospective, randomized, controlled comparison of bupivacaine versus liposomal bupivacaine for pain management after unilateral delayed deep inferior epigastric perforator free flap reconstruction. Plast Reconstr Surg. 2018;141:1327–1330.
28. Gatherwright J, Knackstedt RW, Ghaznavi AM, et al. Comparison of local anesthetic infusion pump bupivacaine versus Transversus Abdominis Plane (TAP) block liposomal bupivacaine for pain management after bilateral deep inferior epigastric perforator free flap reconstruction. J Plast Reconstr Aesthet Surg. 2017;70:1779–1781.
29. Jablonka EM, Lamelas AM, Kim JN, et al. Transversus abdominis plane blocks with single-dose liposomal bupivacaine in conjunction with a nonnarcotic pain regimen help reduce length of stay
following abdominally based microsurgical breast reconstruction. *Plast Reconstr Surg.* 2017;140:240–251.
31. Khansa I, Jefferson R, Khansa L, et al. Optimal pain control in abdominal wall reconstruction. *Plast Reconstr Surg.* 2018;142(3 Suppl):142S–148S.
32. Baxter R, Bramlett K, Onel E, et al. Impact of local administration of liposomal bupivacaine for postsurgical analgesia on wound healing: a review of data from ten prospective, controlled clinical studies. *Clin Ther.* 2013;35:312.e5–320.e5.
33. Little A, Brower K, Keller D, et al. A cost-minimization analysis evaluating the use of liposomal bupivacaine in reconstructive plastic surgery procedures. *Plast Reconstr Surg.* 2019;143:1269–1274.
34. Armstrong K. A primer on local anesthetics for plastic surgery. *Clin Plast Surg.* 2015;40:515–528.
35. Sun T, Sacan O, White PF, et al. Perioperative versus postoperative celecoxib on patient outcomes after major plastic surgery procedures. *Anesth Analg.* 2008;106:950–958, table of contents.
36. Barker JC, DiBartola K, Wee C, et al. Preoperative multimodal analgesia decreases postanesthesia care unit narcotic use and pain scores in outpatient breast surgery. *Plast Reconstr Surg.* 2018;142:443e–450e.
37. Gupta A, Jakobsson J. Acetaminophen, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective inhibitors: an update. *Plast Reconstr Surg.* 2014;134(4 Suppl 2):245–318.
38. Bell S, Rennie T, Marwick CA, et al. Effects of peri-operative non-steroidal anti-inflammatory drugs on post-operative kidney function for adults with normal kidney function. *Cochrane Database Syst Rev.* 2018;11:CD011274.
39. Cawthorn TR, Phelan R, Davidson JS, et al. Retrospective analysis evaluating the use of liposome bupivacaine for postsurgical analgesia on wound healing. *Br J Anaesth.* 2011;106:454–462.
40. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain—a systematic review of randomized controlled trials. *Pain*. 2006;126:91–101.
41. Zhang J, Ho KV, Wang Y. Efficacy of pregabalin in acute postoperative pain: a meta-analysis. *Br J Anaesth.* 2011;106:454–462.
42. Peng PW, Wijeyesundera DN, Li CC. Use of gabapentin for perioperative pain control—a meta-analysis. *Pain Res Manag.* 2007;12:85–92.
43. Hall W, Mackey SC, Schmidt P, et al. Effect of perioperative gabapentin on postoperative pain resolution and opioid cessation in a mixed surgical cohort: a randomized clinical trial. *JAMA Surg.* 2018;153:303–311.
44. Ahuja RB, Gupta R, Gupta G, et al. A comparative analysis of cetonizine, gabapentin and their combination in the relief of post-burn pruritus. *Burns.* 2011;37:203–207.
45. Kaul I, Amin A, Rosenberg M, et al. Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: a retrospective chart review. *Burns.* 2018;44:414–422.
46. United State Food and Drug Administration Drug Safety Communication. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) when used with CNS depressants or in patients with lung problems. 2019. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Accessed May 1, 2020.
47. Gan TJ, Diemunsch P, Habib AS, et al; Society for Ambulatory Anesthesia. Consensus guidelines for the management of postoperative nausea and vomiting. *Anesth Analg.* 2014;118:85–113.
48. Waldron NH, Jones CA, Gan TJ, et al. Impact of perioperative dexamethasone on postoperative analgesia and side-effects: systematic review and meta-analysis. *Br J Anaesth.* 2013;110:191–200.
49. Kainulainen S, Lassus P, Suominen AL, et al. More harm than benefit of perioperative dexamethasone on recovery following reconstructive head and neck cancer surgery: a prospective double-blind randomized trial. *J Oral Maxillofac Surg.* 2018;76:2425–2432.
50. Polderman JAW, Farhang-Razi V, van Dieren S, et al. Adverse side-effects of dexamethasone in surgical patients—an abridged cochrane systematic review. *Anaesthesia.* 2019;74:929–939.
51. Bicket MC, Long JJ, Pronovost PJ, et al. Prescription opioid analgesics commonly unused after surgery: a systematic review. *JAMA Surg.* 2017;152:1066–1071.
52. Hart AM, Broecker JS, Kao L, et al. Opioid use following outpatient breast surgery: are physicians part of the problem? *Plast Reconstr Surg.* 2018;142:611–620.
53. Farley KX, Anastasio AT, Kumar A, et al. Association between quantity of opioids prescribed after surgery or preoperative opioid use education with opioid consumption. *JAMA.* 2019;321:2465–2467.
54. Rose P, Sakai J, Argue R, et al. Opioid information pamphlet increases postoperative opioid disposal rates: a before versus after quality improvement study. *Can J Anaesth.* 2016;63:31–37.
55. Simonis H, Reichsies F, Bornemann-Gimентi H, et al. Standardised pain management decreases expenses on analgesics: results from a 5-year programme at a university hospital. *Eur J Anaesthesiol.* 2018;35:548–550.